Table 3.
Number of deaths from suicide and associated standardized mortality ratios (SMRs) in users of beta-blockers only (n = 26 758), users of calcium channel blockers only (n = 20 142) and users of angiotensin converting enzyme inhibitors only (n = 11 718).
| β-adrenoceptor blockers | Calcium channel blockers | ACE-inhibitors | ||||
|---|---|---|---|---|---|---|
| User status/characteristics | Number observed | SMR (95% CI) | Number observed | SMR (95% CI) | Number observed | SMR (95% CI) |
| Present users | ||||||
| Men | 17 | 1.7 (1.0, 2.7) | 12 | 1.3 (0.6, 2.2) | 7 | 1.4 (0.6, 3.1) |
| Women | 7 | 1.0 (0.4, 2.0) | 4 | 1.0 (0.3, 2.6) | 1 | |
| Both sexes | 24 | 1.4 (0.9, 2.1) | 16 | 1.2 (0.7, 1.9) | 8 | 1.2 (0.5, 2.4) |
| Years of follow-up | ||||||
| < 1 | 15 | 2.1 (1.2, 3.5) | 7 | 1.2 (0.5, 2.3) | 2 | 0.6 (0.1, 2.3) |
| 1–4 | 9 | 1.0 (0.4, 1.8) | 8 | 1.1 (0.1, 3.3) | 6 | 1.7 (0.6, 3.7) |
| 5+ | 0 | 1 | 0 | |||
| Former users* | ||||||
| Men | 7 | 2.2 (0.9, 4.6) | 4 | 1.5 (0.4, 3.8) | 1 | 1.1 (0.0, 6.1) |
| Women | 9 | 3.9 (1.8, 7.4) | 2 | 1.8 (0.2, 6.3) | 1 | 2.2 (0.0, 12.3) |
| Both sexes | 16 | 2.9 (1.7, 4.7) | 6 | 1.6 (0.4, 3.4) | 2 | 1.5 (0.2, 5.3) |
*
No treatment with any of the two other medications.